Teva's 2013 outlook misses estimates
Nov 30 (Reuters) - Teva Pharmaceutical Industries Ltd , the world's biggest generic drugmaker, forecast profit and revenue for the calendar 2013 that fell short of analysts' estimates.
The Israel-based company, which posted a quarterly profit above market estimates earlier this month on strong U.S. revenue, expects an adjusted profit of $4.85 to $5.15 per share in 2013 on revenue of $19.5 billion to $20.5 billion.
Analysts were expecting earnings of $5.71 per share, on revenue of $20.85 billion, according to Thomson Reuters I/B/E/S.
- Maine nurse defies state Ebola quarantine, leaves home |
- Clashes erupt as Israeli police kill Palestinian suspected of shooting Jewish far-rightist
- SoftBank's humanoid robot lands job as Nescafe salesman
- Ukraine gas supplies in doubt as Russia seeks EU payment deal
- Dollar surges as Fed ends QE on hawkish note